Long‐term outcomes for newly‐diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study
Year: 2015
Type: article
Study design: Clinical Trial
Abstract: Long-term outcomes and updated clinical efficacy and safety data were evaluated for newly-diagnosed multiple myeloma patients treated on a phase II study of bortezomib and pegylated liposomal doxorubicin (PegLD). Out of 61 patients, the overall response rate was 57% and the near-complete/complete response rate was 7%. Patients aged ≥65 years old had a higher incidence of treatment-related ≥Grade 3 non-haematological toxicity (80% vs. 51%, P = 0·020). Median overall survival was 5·6 years and negatively impacted by the presence of International Staging System stage III disease, underscoring the need for novel treatment strategies for this group of patients.
Source: British Journal of Haematology
DOI: 10.1111/bjh.13592
Institutions: University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, The University of Texas MD Anderson Cancer Center, Duke Medical Center, Kinston Medical Specialists, University of South Florida, Mayo Clinic, Mayo Clinic in Florida, Mayo Clinic Comprehensive Cancer Center (Florida), The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, University of Chicago, University of Chicago Medicine Comprehensive Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Awards: G1069145923, G10814802, Alliance Statistics and Data Management Center, WUMC Cancer and Leukemia Group B, G1486637521, G1689128559, G199746015, CANCER AND LEUKEMIA GROUP B, G220937036, G2223902704, G237383067, Cancer and Leukemia Group B, G2647518335, Cancer and Leukemia Group B Statistical Center, G3255944410, Southeast Cancer Control Consortium, Inc, Cancer and Leukemia Group B, CANCER AND LEUKEMIA GROUP B--MOUNT SINAI, Cancer and Leukemia Group B - Leukemia Correlative Sciences, Cancer and Leukemia Group B, G3710026009, Cancer and Leukemia Group B: RPCI/SUNYAB, G4192246825, G4670716055, Cancer and Leukemia Group B, CANCER AND LEUKEMIA GROUP B (CALGB), Delaware/Christiana Care Community Clinical Oncology Program, Cancer and Leukemia Group B, G6886639697, CANCER CENTER CALGB PARTICIPATION, G7035163513, MOUNT SINAI COMMUNITY CLINICAL ONCOLOGY PROGRAM, CANCER AND LEUKEMIA GROUP B--MINNESOTA ONCOLOGY GROUP, Cancer and Leukemia Group B, G866232813, G8665016104, Alliance for Clinical Trials in Oncology Operations Center, G877081928, G9000096334, G973482110
OpenAlex ID: W2164963641